NOVO-WARFARIN 3 MG
WARFARIN SODIUM : 3 MG · DIN 02265311 · NOVOPHARM LIMITED
Health Canada status: CANCELLED POST MARKET
What is NOVO-WARFARIN?
NOVO-WARFARIN 3 MG contains WARFARIN SODIUM : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 02265311, held by NOVOPHARM LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 26-Oct-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NOVO-WARFARIN used for?
Prophylaxis/treatment of venous thrombosis, pulmonary embolism, atrial fibrillation with embolization; adjunct in prophylaxis of systemic embolism after MI (stroke, reinfarction, death).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02265311 |
|---|---|
| Brand name | NOVO-WARFARIN |
| Generic / active ingredient | WARFARIN SODIUM : 3 MG |
| Manufacturer | NOVOPHARM LIMITED |
| Strength | 3 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AA03 WARFARIN |
| AHFS class | 20:12.04.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 26-Oct-2015 |
| Original market date | 2005-02-23 00:00:00 |
How is it administered?
Individualized based on PT/INR response. Dosage adjusted to maintain desired PT/INR. Narrow therapeutic range requires periodic monitoring. Refer to conversion from heparin if applicable.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section header present but text cut off).
How is it supplied?
Not explicitly detailed in provided text (mentions 1mg to 10mg strengths).
Contraindications
Hypersensitivity; pregnancy; haemorrhagic tendencies; recent/contemplated CNS or eye surgery; active GI/GU/respiratory tract ulceration; aneurysms; bacterial endocarditis; senility; alcoholism.
Warnings and precautions
Serious risk of haemorrhage and necrosis/gangrene. Narrow therapeutic index. Risk of systemic cholesterol microembolization (purple toe syndrome). Caution in heparin-induced thrombocytopenia.
What can be used instead?
Other Canadian products sharing ATC code B01AA03 WARFARIN. 16 of 60 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-WARFARIN | 1 MG | TABLET | APOTEX INC | MARKETED | DIN 02242924 |
| APO-WARFARIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02242929 |
| APO-WARFARIN | 2 MG | TABLET | APOTEX INC | MARKETED | DIN 02242925 |
| APO-WARFARIN | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02242926 |
| APO-WARFARIN | 3 MG | TABLET | APOTEX INC | MARKETED | DIN 02245618 |
| APO-WARFARIN | 4 MG | TABLET | APOTEX INC | MARKETED | DIN 02242927 |
| APO-WARFARIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02242928 |
| TARO-WARFARIN | 1 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02242680 |
| TARO-WARFARIN | 10 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02242687 |
| TARO-WARFARIN | 2 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02242681 |
Who else supplies WARFARIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. WARFARIN appears in 2044 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.